CUE - Cue Biopharma Inc Stock Price, Fair Value and News

$1.01-0.01 (-0.98%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CUE Price Action

Last 7 days

7.5%

Last 30 days

-7.3%

Last 90 days

94.2%

Trailing 12 Months

-64.2%

CUE RSI Chart

CUE Valuation

Market Cap

64.0M

Price/Earnings (Trailing)

-1.43

Price/Sales (Trailing)

6.71

EV/EBITDA

-1.19

Price/Free Cashflow

-1.67

CUE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CUE Fundamentals

CUE Revenue

Revenue (TTM)

9.5M

Rev. Growth (Yr)

58.86%

Rev. Growth (Qtr)

25.51%

CUE Earnings

Earnings (TTM)

-44.6M

Earnings Growth (Yr)

21.31%

Earnings Growth (Qtr)

14.86%

CUE Profitability

EBT Margin

-556.13%

Return on Equity

-175.87%

Return on Assets

-99.56%

Free Cashflow Yield

-59.89%

CUE Investor Care

Shares Dilution (1Y)

40.39%

Diluted EPS (TTM)

-0.91

CUE Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	7.0M	8.3M	9.5M	0
2023	432.0K	1.8M	3.8M	5.5M
2022	14.4M	11.7M	9.3M	1.2M
2021	3.8M	5.5M	7.2M	14.9M
2020	4.0M	4.0M	3.7M	3.2M
2019	1.7M	2.3M	2.9M	3.5M
2018	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cue Biopharma Inc

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CEO	Mr. Daniel R. Passeri J.D., M.Sc., MSc.
WEBSITE	cuebiopharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	51

Cue Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Cue Biopharma Inc? What does CUE stand for in stocks?

CUE is the stock ticker symbol of Cue Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cue Biopharma Inc (CUE)?

As of Fri Dec 20 2024, market cap of Cue Biopharma Inc is 63.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CUE stock?

You can check CUE's fair value in chart for subscribers.

Is Cue Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether CUE is over valued or under valued. Whether Cue Biopharma Inc is cheap or expensive depends on the assumptions which impact Cue Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CUE.

What is Cue Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CUE's PE ratio (Price to Earnings) is -1.43 and Price to Sales (PS) ratio is 6.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CUE PE ratio will change depending on the future growth rate expectations of investors.